封面
市場調查報告書
商品編碼
1796863

再生傷口護理市場-全球產業規模、佔有率、趨勢、機會和預測,按類型、傷口類型、最終用戶、地區和競爭細分,2020 年至 2030 年

Regenerative Wound Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Wound Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球再生傷口護理市場價值為 102.7 億美元,預計到 2030 年將達到 145.4 億美元,預測期內的複合年成長率為 5.97%。全球再生傷口護理市場正在經歷顯著成長,主要是因為燒傷、受傷、擦傷和潰瘍等造成的傷口發生率不斷上升。此外,老年人口不斷成長,他們容易受到各種傷害和跌倒的影響,預計這將增加對再生傷口護理市場的需求。在老年族群中,由於各種其他相關疾病,傷口癒合過程緩慢,導致對可以加速傷口癒合的產品的需求,從而支持市場成長。根據聯合國經濟和社會事務部人口司的數據,到 2050 年,65 歲或以上人口數量預計將達到 15.489 億。

市場概覽
預測期 2026-2030
2024年市場規模 102.7億美元
2030年市場規模 145.4億美元
2025-2030 年複合年成長率 5.97%
成長最快的領域 門診手術中心
最大的市場 北美洲

關鍵市場促進因素

慢性病盛行率上升

主要市場挑戰

先進再生療法成本高昂

主要市場趨勢

智慧科技在傷口照護中的整合

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:臨床試驗分析

第6章:全球再生傷口護理市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型(自體幹細胞、生物皮膚替代品、組織/多組織平台、胎兒皮膚、再生傷口護理設備、其他)
    • 依傷口類型(潰瘍、手術和創傷性傷口、燒傷)
    • 按最終使用者(醫院、門診手術中心、燒傷護理中心和傷口診所等)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第7章:北美再生傷口護理市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章:歐洲再生傷口護理市場展望

  • 市場規模和預測
  • 市場佔有率和預測
    • B 按類型
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章:亞太再生傷口護理市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章:南美洲再生傷口護理市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章:中東和非洲再生傷口護理市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章:市場動態

  • 驅動程式
  • 挑戰

第13章:市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 14 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 14 章:SWOT 分析:全球再生傷口護理市場

第 15 章:競爭格局

  • DeCell Technologies Inc.
  • Avita Medical, Inc.
  • Organogenesis, Inc.
  • Histogen, Inc.
  • RenovoDerm (Nanofiber Solutions, LLC)
  • StemsysBio
  • Koninklijke DSM NV
  • MiMedx Group, Inc.
  • 3M Company
  • Smith & Nephew PLC

第 16 章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 14405

Global Regenerative Wound Care Market was valued at USD 10.27 billion in 2024 and is expected to reach USD 14.54 billion by 2030 with a CAGR of 5.97% during the forecast period. The global market for Regenerative Wound Care is experiencing significant growth, driven by the growing incidence of wounds caused due to burns, injuries, soars & ulcers, among others. Additionally, the growing geriatric population which is susceptible to various kinds of injuries and falls is expected to increase the demand for regenerative wound care market. In the elderly population, due to various other associated conditions the wound healing process is slow, leading to the demand for products which can bring about faster wound healing, thereby supporting market growth. According to the United Nations, Department of Economic and Social Affairs, Population Division, the number of people aged 65 years or above is expected to reach 1548.9 million by 2050.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 10.27 Billion
Market Size 2030USD 14.54 Billion
CAGR 2025-20305.97%
Fastest Growing SegmentAmbulatory Surgical Centers
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chronic Diseases

One of the most significant drivers of the regenerative wound care market is the growing prevalence of chronic diseases, notably diabetes, obesity, and cardiovascular disorders. These conditions are known to impair wound healing due to poor circulation, reduced immune response, and other metabolic dysfunctions. Among them, diabetes mellitus is the leading cause of chronic wounds, particularly diabetic foot ulcers (DFUs), which are notoriously difficult to treat. Globally, diabetes affects over 537 million adults, and the number is expected to rise to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation (IDF). In the U.S. alone, the CDC reports that over 37 million Americans are diabetic, and 96 million more are prediabetic. Around 15% of diabetic patients develop foot ulcers at some point in their lives, which are susceptible to infections and often require amputation if not effectively treated.

This growing burden is driving demand for advanced and regenerative wound care technologies that can stimulate healing in patients with impaired tissue regeneration. Governments are responding to this healthcare burden with public health initiatives. For instance, the CDC's National Diabetes Prevention Program focuses on early detection, lifestyle intervention, and management strategies that indirectly push for better wound care services. Moreover, the World Health Organization (WHO) has emphasized the growing need for chronic wound care as part of universal health coverage. This global health push is propelling investments in regenerative wound treatments such as stem cell therapies, extracellular matrix products, and skin grafts, especially in middle-income countries seeking to modernize their healthcare systems.

Key Market Challenges

High Cost of Advanced Regenerative Therapies

Despite the promising nature of regenerative wound care solutions, cost remains a formidable barrier to their widespread adoption. Advanced therapies such as stem cell treatments, tissue-engineered skin, and bioactive wound dressings are considerably more expensive than traditional wound care products like gauze or hydrocolloid dressings. For example, the cost of a single application of a bioengineered skin substitute can range from $500 to $3,000, and most treatments require multiple applications. This cost is particularly prohibitive in low- and middle-income countries, where health insurance coverage may be limited or non-existent.

Even in high-income nations, insurance reimbursement can be inconsistent. While programs like Medicare and Medicaid in the U.S. have approved certain products for reimbursement, coverage limitations and complex billing processes often deter hospitals from fully adopting these treatments. In many cases, patients are required to bear out-of-pocket expenses, creating disparities in access. Although governments are attempting to ease the financial burden through subsidies, value-based care models, and innovative payment structures, a lack of uniform policy across regions continues to restrict market penetration. This challenge calls for stronger public-private collaboration to make regenerative wound therapies more economically viable for healthcare systems globally.

Key Market Trends

Integration of Smart Technologies in Wound Care

A key trend in reshaping the regenerative wound care landscape is the integration of digital health and smart technologies into wound management protocols. This includes the use of wearable sensors, artificial intelligence (AI), telehealth platforms, and remote monitoring tools for real-time wound assessment. Smart bandages equipped with biosensors can monitor wound pH, temperature, and moisture levels, providing timely insights into infection risk and healing progress. AI-based diagnostic platforms can assess wounds using image processing and machine learning, reducing diagnostic variability among clinicians and enabling standardized care.

Governments are actively promoting such innovations through health technology initiatives. For instance, the UK's National Health Service (NHS) launched the Wound Care Innovation programme as part of its Long Term Plan to reduce chronic wound burden and treatment costs. Similarly, the U.S. FDA has streamlined digital health regulations via its Digital Health Center of Excellence, encouraging innovation in remote wound care management. These smart technologies not only enhance patient outcomes but also reduce the frequency of hospital visits and the associated costs of chronic wound treatment. This trend is especially relevant in the post-COVID-19 era, where remote patient management has gained acceptance as a viable method for ongoing care, particularly among the elderly and immobile patient populations. The integration of these technologies is set to transform wound care from reactive treatment to proactive management, enabling more effective and efficient care pathways for chronic wound patients.

Key Market Players

  • DeCell Technologies Inc.
  • Avita Medical, Inc.
  • Organogenesis, Inc.
  • Histogen, Inc.
  • RenovoDerm (Nanofiber Solutions, LLC)
  • StemsysBio
  • Koninklijke DSM N.V.
  • MiMedx Group, Inc.
  • 3M Company
  • Smith & Nephew PLC

Report Scope:

In this report, the Global Regenerative Wound Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Wound Care Market, By Type:

  • Autologous Stem Cells
  • Biological Skin Substitutes
  • Tissue/Multiple Tissue Platform
  • Fetal Skin
  • Regenerative Wound Care Devices
  • Others

Regenerative Wound Care Market, By Wound Type:

  • Ulcers
  • Surgical & Traumatic Wounds
  • Burns

Regenerative Wound Care Market, By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Burn Care Centers & Wound Clinics
  • Others

Regenerative Wound Care Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Regenerative Wound Care Market.

Available Customizations:

Global Regenerative Wound Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Regenerative Wound Care Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 6.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 6.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Regenerative Wound Care Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 7.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 7.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Regenerative Wound Care Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Wound Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Regenerative Wound Care Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Wound Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Regenerative Wound Care Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Wound Type
        • 7.3.3.2.3. By End User

8. Europe Regenerative Wound Care Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. B By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 8.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 8.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Regenerative Wound Care Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Wound Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Regenerative Wound Care Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Wound Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Regenerative Wound Care Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Wound Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Regenerative Wound Care Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Wound Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Regenerative Wound Care Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Wound Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Regenerative Wound Care Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 9.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 9.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Regenerative Wound Care Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Wound Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Regenerative Wound Care Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Wound Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Regenerative Wound Care Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Wound Type
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Regenerative Wound Care Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Wound Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Regenerative Wound Care Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Wound Type
        • 9.3.5.2.3. By End User

10. South America Regenerative Wound Care Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 10.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 10.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Regenerative Wound Care Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Wound Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Regenerative Wound Care Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Wound Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Regenerative Wound Care Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Wound Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Regenerative Wound Care Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 11.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
    • 11.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Regenerative Wound Care Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Wound Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Regenerative Wound Care Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Wound Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Regenerative Wound Care Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Wound Type
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products/Services

14. SWOT Analysis: Global Regenerative Wound Care Market

15. Competitive Landscape

  • 15.1. DeCell Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Avita Medical, Inc.
  • 15.3. Organogenesis, Inc.
  • 15.4. Histogen, Inc.
  • 15.5. RenovoDerm (Nanofiber Solutions, LLC)
  • 15.6. StemsysBio
  • 15.7. Koninklijke DSM N.V.
  • 15.8. MiMedx Group, Inc.
  • 15.9. 3M Company
  • 15.10. Smith & Nephew PLC

16. Strategic Recommendations

17. About Us & Disclaimer